Related references
Note: Only part of the references are listed.Convalescent Plasma for the Treatment of COVID-19: Perspectives of the National Institutes of Health COVID-19 Treatment Guidelines Panel
Alice K. Pau et al.
ANNALS OF INTERNAL MEDICINE (2021)
Repurposed Antiviral Drugs for Covid-19-Interim WHO Solidarity Trial Results
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19
M. J. Joyner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19)
Jeroen J. A. van Kampen et al.
NATURE COMMUNICATIONS (2021)
Humoral immune responses and neutralizing antibodies against SARS-CoV-2; implications in pathogenesis and protective immunity
Jorge Carrillo et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2021)
Efficacy and safety of convalescent plasma for severe COVID-19 based on evidence in other severe respiratory viral infections: a systematic review and meta-analysis
Niveditha Devasenapathy et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2020)
Treatment With Convalescent Plasma for Critically Ill Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection
Bin Zhang et al.
CHEST (2020)
Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma
Chenguang Shen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Effectiveness of convalescent plasma therapy in severe COVID-19 patients
Kai Duan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
A human monoclonal antibody blocking SARS-CoV-2 infection
Chunyan Wang et al.
NATURE COMMUNICATIONS (2020)
The Effect of Age on Mortality in Patients With COVID-19: A Meta-Analysis With 611,583 Subjects
Clara Bonanad et al.
JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION (2020)
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study
Fei Zhou et al.
LANCET (2020)
Virological assessment of hospitalized patients with COVID-2019
Roman Woelfel et al.
NATURE (2020)
C-Reactive Protein Level May Predict the Risk of COVID-19 Aggravation
Guyi Wang et al.
OPEN FORUM INFECTIOUS DISEASES (2020)
Remdesivir for the Treatment of Covid-19-Final Report
John H. Beigel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Gender Differences in Patients With COVID-19: Focus on Severity and Mortality
Jian-Min Jin et al.
FRONTIERS IN PUBLIC HEALTH (2020)
Risk factors for 2019 novel coronavirus disease (COVID-19) patients progressing to critical illness: a systematic review and meta-analysis
Lizhen Xu et al.
AGING-US (2020)
Lymphopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A systemic review and meta-analysis
Qianwen Zhao et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2020)
Errors in Trial of Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19
Zhong Liu
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Pooling Data From Individual Clinical Trials in the COVID-19 Era
Eva Petkova et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections
Quan-Xin Long et al.
NATURE MEDICINE (2020)
Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability
Philip J. M. Brouwer et al.
SCIENCE (2020)
An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment
Corine H. GeurtsvanKessel et al.
NATURE COMMUNICATIONS (2020)
Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study
Sean T. H. Liu et al.
NATURE MEDICINE (2020)
Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)
Anup Agarwal et al.
BMJ-BRITISH MEDICAL JOURNAL (2020)
Neutralizing antibodies for the treatment of COVID-19
Shibo Jiang et al.
NATURE BIOMEDICAL ENGINEERING (2020)
Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients
Nisreen M. A. Okba et al.
EMERGING INFECTIOUS DISEASES (2020)
Feasibility of Using Convalescent Plasma Immunotherapy for MERS-CoV Infection, Saudi Arabia
Yaseen M. Arabi et al.
EMERGING INFECTIOUS DISEASES (2016)
Prevention of hepatitis B virus infection: from the past to the future
R. Orlando et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2015)
The Effectiveness of Convalescent Plasma and Hyperimmune Immunoglobulin for the Treatment of Severe Acute Respiratory Infections of Viral Etiology: A Systematic Review and Exploratory Meta-analysis
John Mair-Jenkins et al.
JOURNAL OF INFECTIOUS DISEASES (2015)
Hyperimmune IV Immunoglobulin Treatment A Multicenter Double-Blind Randomized Controlled Trial for Patients With Severe 2009 Influenza A(H1N1) Infection
Ivan F. N. Hung et al.
CHEST (2013)
Passive immunity in the prevention of rabies
Leonard Both et al.
LANCET INFECTIOUS DISEASES (2012)
Use of convalescent plasma therapy in SARS patients in Hong Kong
Y Cheng et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2005)
Share Paper
